Expression and prognostic value of lactoferrin mRNA isoforms in human breast cancer
We investigated the expression levels of human lactoferrin (Lf), a steroid hormone‐inducible gene product the expression of which is often altered during oncogenesis, and of Δ‐lactoferrin (ΔLf), its alternative isoform, which has been shown to be absent from tumor cell lines in commonly used human b...
Gespeichert in:
Veröffentlicht in: | International journal of cancer 2005-03, Vol.114 (2), p.299-306 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | We investigated the expression levels of human lactoferrin (Lf), a steroid hormone‐inducible gene product the expression of which is often altered during oncogenesis, and of Δ‐lactoferrin (ΔLf), its alternative isoform, which has been shown to be absent from tumor cell lines in commonly used human breast epithelial cell lines, using semiquantitative RT‐PCR. Both mRNAs were detected but with levels of expression lower than those found in normal breast epithelial cells. This downregulation was much more visible for ΔLf since its expression was either significantly diminished (BT‐20, MCF‐7 cell lines) or practically absent (MDA‐MB‐231, T‐47D, HBL 100 cell lines). In order to determine whether Lf gene products are useful prognosic tools, we further analyzed their expression levels in 99 primary breast cancer biopsies. ΔLf transcripts were found in all of the samples, whereas Lf transcripts were found in 88% of them. Lf and ΔLf expression levels were positively correlated (p = 0.003). Lf expression was related to tumor type with a higher recovery in lobular‐type tumors (p = 0.04). ΔLf expression was related to the histoprognostic grading (p = 0.02). In univariate analyses, ΔLf and Lf expressions were prognosis parameters, high concentrations being associated with a longer overall survival. © 2004 Wiley‐Liss, Inc. |
---|---|
ISSN: | 0020-7136 1097-0215 |
DOI: | 10.1002/ijc.20728 |